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— Hippocrates (1)SEE PAGE 2952P rimary mitral regurgitation (MR) is a progres-sive disease that is a growing health problembecause of the aging population, and it leads
to a need for mitral valve (MV) surgery when regurgi-
tation is severe and symptoms develop, or signiﬁcant
left ventricular (LV) remodeling and/or dysfunction
exists. Based on the latest U.S. and European guide-
lines, MV repair should also be considered in asymp-
tomatic patients with severe MR, preserved LV
ejection fraction, and resting pulmonary hyperten-
sion (PH) with systolic pulmonary arterial pressure
(SPAP) $50 mm Hg (class IIa) (2,3). MV repair may
also be considered in these patients when PH occurs
at exercise (class IIb) (3).
According to the World Symposium classiﬁcation,
group 2 PH is merely a reﬂection of the hemodynamic
effects of MR (4). The sustained elevation of left atrial
volume and pressure due to chronic volume overload
is passively transmitted backward into the pulmonary
veins, leading to PH (4). The presence of pulmonary
vasoconstriction and progressive pulmonary vascular
remodeling are additional contributors to PH.
The prevalence of PH in MR varies according to
symptomatic status, MR severity, and the presence of*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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mm Hg) is present in 20% to 30% of patients with
severe MR (5,6) and in up to 64% of severely symp-
tomatic patients (New York Heart Association [NYHA]
functional classes III to IV) (7). In asymptomatic
patients, the prevalence of PH is lower, approxi-
mately 6% to 30% (4,8), but increases to 58% during
exercise (8).
Previous small, often heterogeneous, studies have
shown that the presence of PH in patients undergoing
MV surgery is associated with poorer outcomes in
terms of survival, LV dysfunction, limited LV reverse
remodeling, symptom relief, and persistence of PH
(—4-9). Signiﬁcant PH is associated with >2-fold
increased risk of post-operative death (7). Although
long-term survival after MV surgery is inversely
related to the severity of PH, modest increases in
SPAP also adversely affect outcomes (7,9).In this issue of the Journal, these observations
have been elegantly conﬁrmed in the study byMentias
et al. (10), who evaluated the impact of baseline pul-
monary pressures on long-term outcome in primary
MR. This study involved mainly surgical patients
(86%) at low risk (Society of Thoracic Surgeons [STS]
score 3.98  1%) with $3þ MR and preserved LV
function. The investigators reported that age, New
York Heart Association functional class, pre-operative
atrial ﬁbrillation, coronary artery disease, indexed LV
end-systolic diameter, and baseline SPAP $35 mm Hg
were predictors of long-term mortality, whereas MV
surgery was associated with improved survival. They
further showed that the impact of SPAP on outcome
was progressive and not conﬁned to patients with
the highest baseline SPAP values. The use of SPAP also









































Left and Right Hemodynamic Impairment
Left and Right Structural Changes
Left and Right Functional Anomalies
Sym
ptom
atic Deterioration/ Overt Heart Failure
Increased Risk of Cardiac M
orbidity-M
ortality?
Hemodynamic, structural, and functional changes induced by mitral regurgitation are possibly associated with an increased risk of cardio-
vascular events. LA ¼ left atrial; LV ¼ left ventricular; RA ¼ right atrial; RV ¼ right ventricular.
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2963clinical data when incorporated into the clinical model
that included STS score, indexed LV end-systolic
dimension, ﬂail mitral leaﬂet, and MV surgery. SPAP
signiﬁcantly improved reclassiﬁcation for mortality,
even when a threshold of $35 mm Hg was used.
Interestingly, the central message of the study did not
change in terms of SPAP and its incremental prog-
nostic usefulness when analysis was limited to pa-
tients in New York Heart Association functional class I
without atrial ﬁbrillation.
Intriguingly, this low SPAP threshold for better
mortality prediction can be found in older adult pa-
tients without compromised outcome as an impact of
age on LV diastolic properties (11). However, it was
also close to the resting SPAP recently reported by our
group to be more likely associated with exercise
PH, which is a predictor of poor outcome in degener-
ative MR (12). Higher left atrial pressures, lower
atrial compliance, decreased functional reserve with
exercise (left atrial, pulmonary vascular, and right
ventricular function reserve), subtle impairment in
LV systolic and diastolic function, and the dynamic
nature of MR may all contribute to the negativeimpact of even mildly elevated pulmonary pressures.
A higher degree of PH probably indicates more
severe disease with a higher risk of post-operative
morbidity (i.e., right ventricular failure) and mortal-
ity. In the study by Mentias et al. (10), most of
the deaths occurred in the group of patients with
SPAP $50 mm Hg.
Although retrospective, this study is 1 of the largest
on the topic, with sound results and potentially sig-
niﬁcant clinical implications. However, whether post-
operative mortality was related directly to progres-
sive PH remains to be established. Because of the
study’s observational nature, individual progression
of pulmonary pressures was not assessed, and as
such, no follow-up times were pre-speciﬁed for
determining this potential continuum. Also, the cur-
rent study did not indicate whether surgical inter-
vention before PH onset might have improved
prognosis. Finally, the sample size of nonoperated
patients was too small to generalize the ﬁndings to
patients with no indication for MV surgery.
Recent evaluations of the natural history and the
results of interventions have raised the question of
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2964the optimal timing of intervention in patients with
primary MR. The current study supported that sur-
gery should not be delayed in the presence of signif-
icant PH in patients with primary MR. Nevertheless,
waiting for SPAP to progress to $50 mm Hg to treat
MR is likely to expose patients to a mark-
edly compromised prognosis and persistent post-
operative PH. Moreover, the impact of SPAP on
mortality seems to be progressive beyond a level
that is close to $35 mm Hg. In this SPAP category,
the increase in mortality risk is not linear, and as
such, identifying the group of patients in whom
early operative strategy might optimize outcomes is
highly relevant. In these patients, an enlarged
left atrium, decreased global longitudinal function,dynamic MR, exercise-induced severe PH, impaired
exercise capacity, and reduced contractile reserve
are all parameters that might help stratify patient
individual risk (13,14) (Figure 1). Prospective studies
of large cohorts using pulmonary pressure moni-
toring and encompassing most of these out-
come variables would be needed to conﬁrm these
hypotheses.
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